KMO and cancer: Several pharmacological strategies are currently under investigation, including indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors, kynurenine 3-monooxygenase (KMO) inhibitors, and tryptophan mimetics, primarily in the context of cancer, neurodegeneration, and chronic inflammatory diseases [28,29,30].